
Zealand Pharma said Boehringer Ingelheim’s Phase 3 study met its main safety goal and found improvements in several cardiometabolic measures.
Zealand Pharma said Boehringer Ingelheim’s Phase 3 trial of survodutide met its primary cardiovascular safety goal in 5,530 adults with obesity or overweight and elevated cardiovascular risk. The drug did not increase the risk of major adverse cardiovascular events compared with placebo, the company said.
The trial reported a hazard ratio of 0.89 for the primary outcome, with a 95% confidence interval of 0.67 to 1.18. It also found that survodutide did not increase the risk of cardiovascular death, non-fatal stroke or non-fatal heart attack compared with placebo.
At 72 weeks, systolic blood pressure fell by as much as 6.68 mmHg with survodutide, versus 1.76 mmHg with placebo, using the supplementary secondary analysis. Waist circumference fell by as much as 11.96 cm, versus 2.74 cm. The company also reported weight loss of up to 13.7%, compared with 2.0% for placebo.
Nausea, vomiting, diarrhea and constipation were the most common adverse events. Treatment was discontinued because of gastrointestinal events by 19.3% of participants on the 3.6 mg dose and 20.8% on the 6.0 mg dose, compared with 1.9% on placebo.
The results were presented at the American Heart Association Scientific Sessions and published in The Lancet. Zealand said global regulatory submissions for obesity are moving forward. Survodutide remains investigational and has not been approved.
As of 15:08 UTC on Nov. 9, Zealand Pharma shares traded at DKK 243.8, up 4.68% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.